Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii.
about
Extensive Central Nervous System Cryptococcal Disease Presenting as Immune Reconstitution Syndrome in a Patient with Advanced HIV: Report of a Case and Review of Management Dilemmas and StrategiesCryptococcus gattii infectionsIntegrated therapy for HIV and cryptococcosisClinical implications of interferon-γ genetic and epigenetic variantsInvestigating Clinical Issues by Genotyping of Medically Important Fungi: Why and How?Management of Cryptococcus gattii meningoencephalitis.Phenotypic differences of Cryptococcus molecular types and their implications for virulence in a Drosophila model of infection.Antifungal clinical trials and guidelines: what we know and do not knowTreatment and outcomes among patients with Cryptococcus gattii infections in the United States Pacific Northwest.Gastrointestinal cryptococcoma - Immune reconstitution inflammatory syndrome or cryptococcal relapse in a patient with AIDS?Cryptococcosis diagnosis and treatment: What do we know nowParadoxical Immune Responses in Non-HIV Cryptococcal MeningitisDoes the Capsule Interfere with Performance of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Cryptococcus neoformans and Cryptococcus gattii?Post-infectious inflammatory response syndrome (PIIRS): Dissociation of T-cell-macrophage signaling in previously healthy individuals with cryptococcal fungal meningoencephalitis.Cryptococcus antigens and immune responses: implications for a vaccine.Cryptococcus gattii infections: contemporary aspects of epidemiology, clinical manifestations and management of infection.Fatal Cryptococcus gattii genotype AFLP6/VGII infection in a HIV-negative patient: case report and a literature review.Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2014.Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014.Impact of Resistance to Fluconazole on Virulence and Morphological Aspects of Cryptococcus neoformans and Cryptococcus gattii Isolates.What makes Cryptococcus gattii a pathogen?Equine Pulmonary Cryptococcosis: A Comparative Literature Review and Evaluation of Fluconazole Monotherapy.Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.Pulmonary Fungal Diseases in Immunocompetent Hosts: A Single-Center Retrospective Analysis of 35 Subjects.Cryptococcosis in non-HIV/non-transplant patients: A Brazilian case series.Dexamethasone in Cryptococcal Meningitis.Risks of "blind" automated identification systems in medical microbiologyModulating Host Signaling Pathways to Promote Resistance to Infection by Candida albicans.Cryptococcus: Shedding New Light on an Inveterate Yeast.A Call to Arms: Quest for a Cryptococcal Vaccine.Cryptococcosis.Pulmonary cryptococcal infection presenting with multiple lung nodules.Immunology of Cryptococcal Infections: Developing a Rational Approach to Patient Therapy.Cryptococcus gattii Complex Infections in HIV-Infected Patients, Southeastern United States
P2860
Q26852378-97A8DD63-3BBE-42D0-8EBE-190ACC4D22EDQ27002687-A8C04ED8-B8B1-41AC-B0BB-D95DC2832DC8Q28077707-63935FC3-138F-483D-B290-94389CD9799CQ28383437-9578402D-A558-407F-8519-C39FDA40D18AQ29994504-47E6B09D-6FFA-4882-968C-69162A0D9187Q30873978-3B0310DF-C324-4CA0-B208-18CF48496E5EQ33899747-A7159476-A2EC-4BEB-93F3-5613C0E9D74EQ34400255-16AD9331-519D-4C87-9733-5EBDF11BE24AQ35106377-E1B7B24B-F80B-4312-B1A5-1829A782F453Q35311314-94DAD595-C821-472C-9D92-C02228D3C2E3Q35395169-25D4B450-9669-4153-B7FA-5EF9104F7591Q35645083-692A66E0-6F36-45E4-90A4-148EEB6D62E3Q35867195-4C977BD7-8CFE-41CB-B4DA-978077700229Q36781260-6298EBE2-FEBE-4A8F-AB0B-C8062C72A97FQ38155197-25758997-8BFA-49D4-87C7-AD3E9EE493D8Q38165199-6692C23E-D679-4D85-8EAE-EE2E0D093441Q38224820-AA7A34A6-3E7F-4937-B8D1-FB4BADD2ED11Q38284447-CF28A7E6-FC2F-46B9-9061-52C758AE1102Q38284461-5DA98E2C-FC0C-493A-8350-4677F1B150C4Q38467366-2058AAE5-6DB2-421A-91BD-B90683C7C989Q38650835-4ED4208F-20B2-4D81-A324-BD2EEA2ADE37Q38961238-F267F47E-5BA2-46F0-AB8F-FB537D24C421Q39064815-49E8AEC5-7D38-4F06-AE06-24A654200527Q40675467-40B73C02-A39B-437E-A820-0433BBD41D2BQ40697279-FBF6C20F-6B13-48C7-845A-13B2E993A7C2Q42355220-FCBC0E15-254E-4633-8448-D857890C2ABAQ42745311-1687B224-B4F3-4C55-8290-0B0F0135318BQ47334511-ED4A52C8-5BD7-4F69-87CD-C01CE2204A3DQ47548230-D58F5379-C596-4D0F-854E-55EB9A9E43CFQ50149203-C101F34F-4C4D-47A9-A346-B974DD28DB1BQ51818572-CEA0D7B3-6756-437D-A3E5-F781FEF77B50Q54241649-A14D940F-A375-4F64-A0A4-42D970A15966Q54953513-51061FFC-1FD3-468F-BE05-6D5ABA9BE094Q58550710-5F0C23A2-4E66-4828-A779-7E3AC8824EE7
P2860
Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Antifungal therapy and managem ...... is due to Cryptococcus gattii.
@en
Antifungal therapy and managem ...... is due to Cryptococcus gattii.
@nl
type
label
Antifungal therapy and managem ...... is due to Cryptococcus gattii.
@en
Antifungal therapy and managem ...... is due to Cryptococcus gattii.
@nl
prefLabel
Antifungal therapy and managem ...... is due to Cryptococcus gattii.
@en
Antifungal therapy and managem ...... is due to Cryptococcus gattii.
@nl
P2093
P2860
P50
P356
P1476
Antifungal therapy and managem ...... is due to Cryptococcus gattii.
@en
P2093
Australia and New Zealand Mycoses Interest Group (ANZMIG) Cryptococcus Study
Christopher H Heath
Deborah Marriott
E Geoffrey Playford
Karen Byth
Krispin Hajkowicz
Ronan Murray
Sharon C-A Chen
P2860
P304
P356
10.1093/CID/CIT341
P407
P50
P577
2013-05-22T00:00:00Z